Hongying Gao

TL;DR: Although PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.

TL;DR: In this paper, the potential opportunities and challenges of PROTAC-induced targeted protein degradation have been discussed, which will contribute to the research and development of new protein degradation drugs and degrader tools.

TL;DR: A focused PROTAC library hijacking cancer therapeutic target CDK6 was developed and strongly inhibited proliferation of haematopoietic cancer cells including multiple myeloma and robustly degraded copy-amplified/mutated forms ofCDK6, indicating future potential clinical applications.

TL;DR: Wang et al. as mentioned in this paper developed first-in-class CDK2-targeted proteolysis-targeting chimeras (PROTACs), which promoted rapid and potent CDK 2 degradation in different cell lines without comparable degradation of other targets.

TL;DR: A novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus, and others.